Award
National Cancer Institute 5R44CA278570-02
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
Recipient
Not Specified
Award Amount
$995,099.00
Ceiling
$995,099.00
Awarded
August 16, 2024
Identifier
5R44CA278570-02
NIH SBIR Phase 2 award for developing an immunomodulating peptide therapy for osteosarcoma in canine and human, including IND enabling, manufacturing, and clinical trial preparations.
Description
This is a NIH SBIR Phase 2 project focused on developing an immunomodulating peptide for osteosarcoma treatment, with a focus on both canine and human applications. The project includes IND enabling activities, manufacturing, and clinical trial preparations.